Biotech Values

[jq1234]

As far as I know, they haven't received meeting minutes. I actually don't follow SRPT as closely I used to. All I care about at this point is what ph3 design will be like. I responded here today because so many SRPT postings off one article.

RNA will engage regulators in 2Q per their previous guidance. Again, I don't follow RNA on daily basis either. Changing drisa from subc to IV at this point isn't that simple, almost have to start from scratch. If ph3 had succeeded, they could do a bridge study to get new formulation approved. Now it is more complicated. They do use or plan to use IV formulation for other exon skipping candidates to get better exon skipping efficiency.